Rua Bioscience shareholders have overwhelmingly approved the purchase of Zalm, throwing further shareholder weight behind the company’s bid to become New Zealand’s premier medicinal cannabis company. The purchase will be undertaken through the issue of 28,735,632 shares over three years to Zalm Therapeutics shareholders based on the achievement of agreed milestones.
